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Abstract 
Introduction: Increasing numbers of patients with breast cancer receive neoadjuvant therapies. We investigated 
differences in survival rates between geriatric and non-geriatric patient groups following administration of 
neoadjuvant therapies. Materials and Method: We examined 166 patients who received neoadjuvant therapy for 
breast cancer between 2007 and 2016. Patients <70 years were in Group 1 and those ≥70 years were in Group 2. We 
retrospectively compared age, sex, treatment, tumour stage and localisation, status of oestrogen and progesterone 
receptors, involvement of axillary lymph nodes, systemic treatment complications, treatment compliance and 
survival rates using a variety of parametric and non-parametric statistical tests. Results: The mean ages of patients 
in Group 1 [n = 136] and Group 2 [n = 30] were 44.6 ± 8.92 and 76.7 ± 5.48 years, respectively. The most common 
tumour location was the upper-outer quadrant. All patients received treatment consisting of 4AC [doxorubicin-
cyclophosphamide] + 4 taxane or 4AC [doxorubicin-cyclophosphamide] + paclitaxel for 12 weeks. Neither group 
exhibited mortality or complications requiring treatment interruption. Breast-conserving surgery was performed in 
88 [53%] patients. Complete response was achieved in 14 [8%] patients after surgery. Mean tumour diameters in 
Groups 1 and 2 were 26.8 mm [±27.59] and 28.5 mm [±40.23], respectively. Five-year general survival rates were 
% 69,7 in Group 1 and % 70 in Group 2[ p = 0.94]. Conclusion: Neoadjuvant therapy is a reliable treatment option 
in patients ≥70 years who are candidates for chemotherapy, since complication and mortality rates did not increase 
compared with younger patients. 
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Introduction 
For females in both developed and developing 
countries, breast cancer has the second highest 
mortality rate after lung cancer. More than 1.3 million 
individuals are diagnosed with breast cancer each year, 
and the mortality rate is 60% in developing countries 
[1-2]. Some studies have reported that in American 
women, the probability of developing breast cancer is 
12.3% [3]. Presently, various factors such as genetic 
predisposition, hormones, lifestyle and age play an 
etiological role in this disease [4]. 
Approximately 7% of patients with breast cancer are 
diagnosed before age 40 years [5] and the risk for 
breast cancer increases with age.  
_________________________ 
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The most critical factors affecting the survival of 
patients with breast cancer are early diagnosis, tumour 
stage and age [3,6,7]. 
Neoadjuvant therapy can reduce tumour size and may 
provide a higher chance for breast-conserving surgery 
[BCS]. Additionally, and perhaps more importantly, 
achieving pathological complete response of 50%–60% 
in axillary-positive patients may allow the performance 
of sentinel node biopsy instead of axillary dissection in 
patients with axillary downstage. Thus, lymphoedema 
due to axillary dissection, restricted shoulder range of 
motion, numbness and reduced quality of life are 
potentially prevented. Also, treatment modification 
may be performed by in vivo monitoring of 
chemotherapeutic responses of an existing tumour. 
Studies report high rates of pathological complete 
responses and, consequently, remarkable survival 
advantages in patients who received  neoadjuvant 
therapy Consequently, neoadjuvant therapy appears to 
be a good treatment option for some patients as it 
increases the chances that BCS [rather than 
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mastectomy] can be performed by reducing tumour 
size [2,5-7]. This less drastic, surgical approach holds 
both psychological and cosmetic advantages [4]. 
In Literacy prognosis of premenopausal patients with 
breast cancer was worse than that of postmenopausal 
females.[8] Despite these findings, administration of 
neoadjuvant therapies associated with favourable 
outcomes in younger patients is generally considered 
more deliberately in elderly patients [2,9]. Various 
studies on the effects of neoadjuvant therapy have been 
conducted; however, these focused on patients <65 
years [10,11], and there are little outcomes data 
pertaining to neoadjuvant therapy in older patients. We 
sought to investigate differences in survival rates 
between geriatric and non-geriatric patient groups 
following administration of neoadjuvant therapies for 
breast cancer. 
 
Materials and Method 
Study profile and data collection 
 
We retrospectively analysed patients who were 
followed up between 2007 and 2016. Patients <70 
years old were designated as Group 1 and those ≥70 
years were Group 2. This study was approved by the 
Istanbul University Ethical Committee approval. 
Patient characteristics 
Patients were treated with the following protocol: 4AC 
[doxorubicin-cyclophosphamide] + 4 taxane or 4AC 
[doxorubicin-cyclophosphamide] + paclitaxel for 12 
weeks. Patients were followed for hematologic toxicity 
[neutropenia, thrombocytopenia], hepatic toxicity, 
nephrotoxicity, nausea and vomiting associated with 
chemotherapy drugs, deterioration of the general 
condition of the patient, decrease in functional capacity 
during treatment. Routine clinical and radiological 
examinations [mammography, breast ultrasound and 
breast magnetic resonance imaging] were completed 
prior to and following treatment to determine treatment 
response. Herceptin was added to the treatment 
regimen of HER2-positive patients. HER 2 positive 
patients took Trastuzumab during neodjuvan therapy 
and after the surgery.  
 
Statistical analysis 
Study data were evaluated using descriptive statistical 
methods, such as averages, standard deviations, 
frequencies and percentages, whereas variable 
distributions were assessed using the Kolmogorov–
Smirnov test. Student’s t-tests and Mann–Whitney U-
tests were used to analyse quantitative data while 
qualitative data were analysed using the Chi-square 
test. Kaplan–Meier analysis was used to determine 
survival rates, and the log-rank test was used to 
perform comparisons. SPSS 24.0 software was used in 
the analysis of study data. The level of statistical 
significance was accepted as p < 0.05. 
 
Results 
 
Our study included 166 patients. Group 1 [<70 years] 
consisted of 136 patients, whereas Group 2 [≥70 years] 
consisted of 30 patients. The mean age of the study 
group was 49.50 ± 13.42 [26–89] years. Breast tumour 
was most commonly found in the right breast and 
upper-outer quadrant. BCSs were performed in 88 
patients. Demographic data are shown in Table 1. 
Table 1: Demographic data 
 Group 1 <70 Group 2 ≥70 p 
Mean age 44.60 ± 8.92 76.73 ± 5.48 0,005 
Mean ASA  1.13 ± 0.34 2.4 ± 0.81 <0.001 
Presence of comorbidity 19 30  
 N % n %  
Operation BCS 73 53.7 15 50 0.434 
Mastectomy 63 46.3 15 50 
Quadrant Lower outer 19 14 6 20 0.960 
Lower inner 14 10.3 3 10 
Upper outer 57 41.9 12 40 
Upper inner 18 13.2 3 10 
Overlapping 11 8.1 3 10 
Central  17 12.5 3 10 
Pathological  regression 
rate 
 65.89 ± 32.9  68 ± 34.87  0.557 
ASA: American Society of Anesthesiologists classification BCS: Breast conserving surgery 
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One hundred and thirty-nine patients were 
administered the 4AC-4T treatment regimen, and no 
statistically significant difference was found between 
the results of the administered treatment regimens [p > 
0.05]. In the content of these treatment regimens, 4AC 
+ 12p treatment protocol was performed instead of 
4AC + 4T in elderly patients. Pathological  regression 
rates were 66% and 68% in Groups 1 and 2 patients, 
respectively [p>0.05]. There were no differences 
between the clinical stages of patients prior to 
chemotherapy. Pathological examination revealed no 
tumour in 20 patients who underwent surgery after 
neoadjuvant therapy. The patients most commonly 
received surgery during the cT2 stage. Pathological 
complete response rates [pCRs] were 8% in Group 1 
patients and 30% in Group 2 patients [p=0.01]. [Table 
2].  
 
Table 2: Postoperative stages 
 Group 1 <70 Group 2 ≥70 p 
n % n % 
T stage 0 11 8.1 9 30 0.01 
1 12 8.8 3 10 
2 59 43.4 6 20 
3 38 27.9 9 30 
4 16 11.8 3 10 
N stage 0 24 17.6 12 40 0.001 
1 84 61.8 15 50 
2 25 18.4 0 0 
3 3 2.2 3 10 
 
In Group 1, 81 patients [59%] were oestrogen receptor-
positive and 59 [43%] were progesterone receptor-
positive. In Group 2, 15 patients [50%] were oestrogen 
receptor-positive and three patients [10%] were 
progesterone receptor-positive [p = 0.224 and p = 
0.001, respectively]. Lymphovascular invasion was 
found in 69 patients [Table 3]. 
 
Table 3: Pathological data 
 
 Group 1 <70 Group 2 ≥70 p 
Residual Tumour Size 26.81 ± 27.59 28.50 ± 40.23 0.020 
Oestrogen receptor [+] 81 [59%] 15 [50%] 0.224 
Progesterone [+] 59 [43%] 3 [10%] 0.000 
Lymphovascular invasion [+] 57 [41%] 12 [40%] 0.508 
Necrosis [+] 17 [12%] 3 [10] 0.493 
HER2 [+] 17 [12%] 3 [10%] 0.493 
 
No patient died during treatment and there were no 
toxicity events that required the interruption of 
chemotherapy in either group. No differences between 
groups were found in surgical complications 
[hematoma,wound infectionand seroma]. Mean 
survival duration was 79.103 ± 4.057 [71.152–87.054] 
months. Disease relapse was determined in 24 and 3 
patients in Groups 1 and 2, respectively. Median 45-
month [1–116 months] follow-up revealed disease-free 
survival rates of 92.599 ± 4.22 [Group 1] and 86.500 ± 
5.20 [Group 2; p = 0.184]. Five-year overall survival 
rates were  were %69,7 in Group 1 and % 70 in Group 
2. An evaluation of mean survival rates between the 
groups showed no statistically significant difference, 
although survival rate of Group 1 patients was slightly 
higher [p = 0.94].  
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Figure 1: Overall survival 
Figure 2: Disease-free survival 
 
Discussion 
Follow-up and treatment of breast cancer is an 
important public healthcare problem and, despite 
diagnostic and treatment advances, is more 
complicated in elderly patients than in younger 
patients. Patient age is a critical risk factor for breast 
cancer. A study out of the United States of America 
indicated that geriatric patients frequently present with 
invasive breast cancer. Approximately 50% of the new 
cases were among older patients [5,6]. Age 70 is an 
important cut point for breast cancer risk. The risk of 
developing breast cancer is higher in women ≥70 years, 
and breast cancer treatment is a more complicated 
proposition in this population because of comorbidities 
[5,7,12]. Patients ≥70 years are considered “geriatric”; 
therefore, we sought to compare treatment outcomes 
between patients with breast cancer who were <70 
years and those aged ≥70 years. 
Survival rates of patients with breast cancer improve 
depending on early diagnosis, treatment model and 
accurate regulation of follow-up visits. Developments 
in early diagnosis and treatment reduced annual 
mortality rates related to breast cancer to <36% [3,12]. 
Many studies that examined survival in patients with 
breast cancer focused on the relationship between 
survival and early diagnosis or tumoural invasion. 
Studies that examined treatment response relative to 
age were usually associated with younger patients; 
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existing data on treatment responses among geriatric 
patients is limited [7,12]. The present study contributes 
novel insights to this topic since we analysed responses 
to neoadjuvant therapy in geriatric patients with breast 
cancer compared with those in younger patients with 
breast cancer. 
Difference in response rates to neoadjuvant therapies 
between younger and older patients is an important 
issue. In our study, pCR was higher in geriatric patients 
than in non-geriatric patients. Tumour biology 
revealing higher PR-negative and higher HER2-
positive levels in geriatric patients receiving 
neoadjuvant therapy may explain the higher complete 
response rates. The fact that pCR in geriatric patients 
was not worse than that observed in non-geriatric 
patients is an important finding that may support the 
use of neoadjuvant therapies in geriatric patients. 
Adjuvant chemotherapy may not be preferred for use in 
geriatric patients because of concerns including 
medication side effects or the potential for 
chemotherapeutic resistance, which may develop 
during treatment [10,13]. Neoadjuvant therapies should 
also be considered as potential treatments in geriatric 
patients with breast cancer; however, studies on this 
subject are limited. Of note, neoadjuvant therapy 
increases survival rates in addition to its known 
advantages including monitorisation of treatment 
response. Additionally, adjuvant therapy may increase 
the chance of BCS in patients with pCR [10]. In our 
study, the 5-year survival rate was 76% in patients who 
received neoadjuvant therapy and 66% in geriatric 
patients. Although survival may vary depending on 
many factors, our outcomes are in agreement with 
existing literature [2,1,14-16]. 
The term “geriatric oncology” was first suggested in 
2003 and has received increasing attention in recent 
years [17]. According to the WHO data, individuals 
aged 66–79 and 80–99 years are considered of 
“middle” and “elderly” ages, respectively. Even as the 
human lifespan continues to lengthen, the accepted age 
ceiling for neoadjuvant therapy remains 70 years in the 
current common practice. Prior to 1980’s, elderly 
patients were often excluded from studies, whereas 
outcome data increasingly include that of elderly 
patients [18]. The assertion that chemotherapy provides 
better responses in younger patients is inconsistently 
supported by existing data. Some studies report milder 
side effects of chemotherapy in younger than in elderly 
patients. On the other hand, another study found that 
biological age was more important than chronological 
age when examining tolerance to standard 
chemotherapy in elderly patients. According to several 
studies, elderly patients present to oncologists during 
earlier tumour stages. Distant metastases develop more 
frequently in elderly patients than in younger patients 
with the same tumour stage who receive the same 
treatment [19,20]. This outcome suggests that more 
aggressive therapy may be indicated in elderly patients. 
The treatment protocols set forth by the NCCN 
Oncology Outcomes Database for Breast Cancer can be 
used to minimise toxicity; however, cancer treatment 
should be individualised. During the decision-making 
process, the patient’s biological characteristics should 
be taken into account in addition to tumour-associated 
factors [21]. Patient preference is another important 
consideration. Age should not be taken as the sole 
restrictive factor during the decision-making process. 
The patient’s biological age, disease stage, tumour 
characteristics, expected response after chemotherapy, 
disease-free survival duration and preferences require 
consideration in addition to the chronological age. 
The positive effects of the postmenopausal period on 
treatment also require attention [8,10]. Neoadjuvant 
therapy improves life quality by helping the patient 
psychologically and facilitating adaptation to life 
circumstances. Additionally, it can reduce tumour size, 
thereby helping conserve breast tissue by BCS and 
increasing the chance of cure [5,15,17,22]. Bleyer et al. 
found that younger female patients had a higher chance 
of survival than elderly female patients across all 
disease stages [23]. However, another study found that 
the rate of local relapse after mastectomy was nine-fold 
higher in young female patients than that in elderly 
female patients [9]. All in all, young and elderly 
patients may show different survival rates; however, 
this can be attributed to the biological status of both 
age groups [5]. The outcomes of our study suggest that 
neoadjuvant therapy may provide favourable results 
not only in the treatment of patients with breast cancer 
aged <70 years old but also in geriatric patients ≥70 
years. Breast preservation may also afford 
psychological benefits. 
Presently, a commonly preferred neoadjuvant treatment 
regimen without age limit is anthracycline, 
cyclophosphamide and taxane-based chemotherapy 
[10]. We preferred this treatment regimen for most of 
the patients in our study. Besides this regimen, several 
studies reported that administration of weekly 
paclitaxel as a taxane treatment is easier and safer in 
patients with comorbidities. In our study, there were no 
differences in complications that required treatment 
interruption and in treatment responses between the 
administrations of weekly paclitaxel and docetaxel 
once every 3 weeks [p>0.05]. Nevertheless, there are 
many studies which have reported that paclitaxel can 
be administered weekly, is well-tolerated and is 
associated with similar response rates in elderly patient 
with comorbidities. 
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In conclusion, geriatric patients with breast cancer who 
received neoadjuvant therapy showed similar treatment 
results compared with non-geriatric patients with breast 
cancer. Since many studies published on this subject 
have shown that there were no differences between the 
outcomes associated with either adjuvant or 
neoadjuvant therapy, neoadjuvant therapy may help 
improve the quality of life for geriatric patients and 
should stand as a treatment option for these individuals. 
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